Raman Spectroscopic Analysis of Bronchoscopic Biopsy for Diagnosing Lung Cancer

China-Japan Friendship Hospital200 enrolled

Overview

The goal of this clinical trial is to evaluate raman spectroscopic analysis of bronchoscopic biopsy for diagnosing lung cancer in visible lesions in the airway. The main question it aims to answer are: the diagnostic efficacy raman spectroscopic analysis of bronchoscopic biopsy for diagnosing lung cancer. The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

200

Conditions

Lung Cancer

Interventions

Raman spectrumDIAGNOSTIC_TEST

The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who plan to undergo bronchoscopic biopsy or EBUS-TBNA * Visible intratracheal lesions under bronchoscope * Non-visible lesions suspected of lung cancer Exclusion Criteria: * The patient could not tolerate further examination aimed at clarifying the cause of the disease or refused to accept further examination aimed at clarifying the cause of the disease due to poor general condition, serious organ dysfunction, etc * The patient has no definite diagnosis

Outcomes

Primary Outcomes

To establish the sensitivities and specificities of Raman spectroscopic analysis of bronchoscopic biopsy for lung cancer.

The diagnosis would be confirmed according to the pathological results.

Time frame: 7 days after the biopsy

Central Contacts

Mingming Deng, MD

CONTACT

86 18801336854 isdeng1017@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.